Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)
China · Delayed Price · Currency is CNY 3.360
+0.010 (0.30%)
Apr 28, 2026, 3:04 PM CST
SHE:300026 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,941 | 5,757 | 6,025 | 6,603 | 7,656 |
Other Revenue | - | 26.24 | 84.31 | 47.44 | 14.63 |
| 4,941 | 5,783 | 6,109 | 6,650 | 7,671 | |
Revenue Growth (YoY) | -14.55% | -5.34% | -8.14% | -13.30% | 18.22% |
Cost of Revenue | 2,060 | 2,793 | 2,827 | 2,826 | 3,267 |
Gross Profit | 2,881 | 2,989 | 3,282 | 3,824 | 4,403 |
Selling, General & Admin | 2,288 | 2,534 | 2,463 | 2,751 | 3,054 |
Research & Development | 197.74 | 223.45 | 209.81 | 230.85 | 196.59 |
Other Operating Expenses | 33.41 | 48.74 | 41.4 | 61.72 | 76.44 |
Operating Expenses | 2,519 | 2,887 | 2,767 | 3,100 | 3,401 |
Operating Income | 361.75 | 102.42 | 515.52 | 724.42 | 1,002 |
Interest Expense | - | -44.86 | -61.57 | -69.67 | -50.1 |
Interest & Investment Income | - | 17.31 | 19.31 | 14.18 | 11.38 |
Currency Exchange Gain (Loss) | - | 3.92 | 2.41 | 17.62 | -6.34 |
Other Non Operating Income (Expenses) | -109.92 | -22.2 | -18.49 | -35.65 | -26.86 |
EBT Excluding Unusual Items | 251.82 | 56.59 | 457.19 | 650.91 | 930.58 |
Impairment of Goodwill | - | -17.34 | -23.52 | - | -58.18 |
Gain (Loss) on Sale of Investments | -3.66 | -5.63 | -1.4 | - | -22.98 |
Gain (Loss) on Sale of Assets | 0.7 | 1.08 | 1.06 | 0.01 | -2.87 |
Asset Writedown | -166.22 | -30.33 | -4.05 | -2.36 | -9.35 |
Other Unusual Items | - | 49.62 | 177.54 | 67.82 | 16.99 |
Pretax Income | 82.65 | 53.98 | 606.82 | 716.37 | 854.18 |
Income Tax Expense | 60.42 | 31.04 | 105.25 | 95.14 | 183.32 |
Earnings From Continuing Operations | 22.22 | 22.95 | 501.57 | 621.23 | 670.85 |
Minority Interest in Earnings | -3.73 | -1.48 | 5.06 | 3.01 | 16.47 |
Net Income | 18.5 | 21.47 | 506.63 | 624.24 | 687.32 |
Net Income to Common | 18.5 | 21.47 | 506.63 | 624.24 | 687.32 |
Net Income Growth | -13.84% | -95.76% | -18.84% | -9.18% | 19.87% |
Shares Outstanding (Basic) | 1,850 | 2,147 | 2,980 | 2,973 | 2,988 |
Shares Outstanding (Diluted) | 1,850 | 2,147 | 2,980 | 2,973 | 2,988 |
Shares Change (YoY) | -13.84% | -27.97% | 0.26% | -0.53% | -0.98% |
EPS (Basic) | 0.01 | 0.01 | 0.17 | 0.21 | 0.23 |
EPS (Diluted) | 0.01 | 0.01 | 0.17 | 0.21 | 0.23 |
EPS Growth | - | -94.12% | -19.05% | -8.70% | 21.05% |
Free Cash Flow | 681.09 | 659.12 | 1,183 | -24.93 | -285.85 |
Free Cash Flow Per Share | 0.37 | 0.31 | 0.40 | -0.01 | -0.10 |
Dividend Per Share | - | 0.030 | 0.030 | 0.030 | 0.040 |
Dividend Growth | - | - | - | -25.00% | - |
Gross Margin | 58.31% | 51.69% | 53.73% | 57.50% | 57.40% |
Operating Margin | 7.32% | 1.77% | 8.44% | 10.89% | 13.07% |
Profit Margin | 0.37% | 0.37% | 8.29% | 9.39% | 8.96% |
Free Cash Flow Margin | 13.78% | 11.40% | 19.36% | -0.38% | -3.73% |
EBITDA | 644.01 | 387.15 | 807.69 | 974.09 | 1,217 |
EBITDA Margin | 13.03% | 6.69% | 13.22% | 14.65% | 15.86% |
D&A For EBITDA | 282.26 | 284.74 | 292.17 | 249.67 | 214.2 |
EBIT | 361.75 | 102.42 | 515.52 | 724.42 | 1,002 |
EBIT Margin | 7.32% | 1.77% | 8.44% | 10.89% | 13.07% |
Effective Tax Rate | 73.11% | 57.49% | 17.34% | 13.28% | 21.46% |
Revenue as Reported | - | 5,783 | 6,109 | 6,650 | 7,671 |
Advertising Expenses | - | 8.6 | 9.15 | 12.6 | 21.21 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.